Skip to content

2APharma

Biopharmaceutical company

  • Home
  • ABOUT US
  • VACCINE PLATFORM
  • PIPELINE
    • OVERVIEW
    • 2AP01
    • 2AP02
    • 2AP03
    • 2AP05
    • 2AP07
  • NEWS
  • CONTACT US

EUROSTARS FUNDING FOR THERAPEUTIC HEAD AND NECK CANCER VACCINE PROJECT

September 27, 2018

We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07, a project to develop a therapeutic head and neck cancer vaccine.

Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths per year. Our AAVLP-HNC vaccine has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines.

Back

Denmark

2A Pharma ApS
Niels Jernes Vej 10
9220 Aalborg Øst
Denmark

CVR No.: 3939 1597
VAT No.: DK 3939 1597

Sweden

2A Pharma AB
Södergatan 3
211 34 Malmö
Sweden

Registration No.: 559090-2788
VAT No.: SE55 9090 2788 01

Pipeline

  • 2AP01 HPV
  • 2AP02 Breast Cancer
  • 2AP03 Allergic Diseases
  • 2AP04 Alzheimer's
  • 2AP05 Autoimmune Diseases
  • 2AP06 HIV
  • 2AP07 Head and Neck Cancer
  • Subscribe to our newsletters

    Contact

    +45 7214 6700
    info@2apharma.com